CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.
“This randomized study should answer the question of whether CRLX101 can meaningfully impact an area of severely unmet medical need.”
With the 150-patient randomized Phase 2 study in advanced non-small cell lung cancer expected to read out soon, Cerulean is broadening the CRLX101 opportunity in lung cancer.
Arrowhead Research Corp Clinical development update by Edison Investment Research dated 3 Jan, 2013
"Arrowhead continues to make good progress in R&D and business development, reporting in recent weeks encouraging preclinical data on the anti-HBV compound ARC 520 and the signing of a licensing deal with Shire for its peptide library. ARC 520 is on track to enter clinical development this year, while data from studies of Arrowhead’s two clinical-stage compounds CALAA-01 (cancer) and Adipotide (obesity) are due in early/mid 2013. These events, plus potential royalties on Cerulean’s CRLX101 in non small-cell lung cancer, have the potential to boost our current $60m valuation, which is solely based on CALAA-01 and Adipotide."
This is encouraging!